Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HR+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant, Nurse, Pharmacist, Respiratory Therapist
Target Specialties: Oncology, Hematology/Oncology

Mali Barbi

Northwell cancer center

I’m a medical oncologist specializing in gynecologic and breast cancers, with a strong interest in translational research using patient-derived organoids to better understand tumor biology, treatment response, and disparities in women’s cancers. I’m passionate about bridging the gap between lab discoveries and clinical impact, and love collaborating across disciplines to bring new therapies to patients.